Disease progression to crizotinib was reported in an ALK-rearranged patient with c-Met overexpression and Her-2 amplification [42].The clinical and therapeutic implications of c-Met overexpression underlay in ALK- rearranged NSCLC patients were undiscovered. Here, ERBB2 is linked to non-small cell lung carcinoma.